Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

A 12-Month, Phase 4, Open Label, Multicenter, Trial to Assess the Efficacy and Safety of COMBIGAN® in Korean Patients With Primary Open Angle Glaucoma (POAG) and Normal Tension Glaucoma (NTG)

The objective of this study is to evaluate the long-term efficacy and safety of COMBIGAN® (brimonidine tartrate/timolol malate) in patients only using COMBIGAN® (brimonidine tartrate/timolol malate) and also in patients who require additional IOP lowering with LUMIGAN® (bimatoprost) 0.01%.

Inclusion Criteria:

• Patients with Primary open angle glaucoma (Regardless of Intraocular pressure)
• Previous history of topical beta-blocker use and insufficiently controlled IOP

Exclusion Criteria:

• Pigmentary or exfoliative glaucoma
• History of angle-closure or an occludable angle by gonioscopy
• Prior filtration or laser iridotomy
• Argon laser trabeculoplasty or Selective laser trabeculoplasty performed less than 6 months
• History or signs of chronic inflammatory eye disease, ocular trauma, or potentially progressive retinal disease